[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
The aim of the study was to evaluate the correlation between hemostatic parameters such as: the activity of antithrombin III and factor X, thrombin generation, clot bound thrombin, fibrinogen and serum lipids in patients (pts) with hyperlipidemia (hlp) type II after 2-months treatment with simvastatin in dose 20 mg/day.


METHODS
The study involved 22 pts with hip with the initial concentrations of total cholesterol (TC) > 230 mg/dL, LDL-cholesterol (LDL-C) > 130 mg/dL, triglicerides (TG) < 400 mg/dL, 22 healthy volunteers as the control group. The hemostatic parameters and serum lipids were estimated before and after active therapy. TC, HDL-C, TG were determined by enzymatic method, LDL-C was calculated by Friedewald'a formula. Thrombin generation and clot bound thrombin levels were estimated by spectrophotometric method with usage of chromogenic substrate S-2238, the activity of factor X and antithrombin III--by amidolytic methods. For correlation we used coefficient of linear correlation.


RESULTS
After 2-months therapy with simvastatin in patients with hlp II it was observed significantly decrease of activity of factor X (20.94 +/- 19.04 vs. 9.44 +/- 7.31 mU/mL), thrombin generation (79.62 +/- 36.68 vs. 67.99 +/- 37.69 U/mL), clot bound thrombin (49.73 +/- 21.17 vs. 37.08 +/- 26.10 U/mL) and increase of antithrombin III activity (13.03 +/- 6.11 vs. 20.64 +/- 4.18 U/mL). The mean concentrations of fibrinogen didn't change during statin treatment (336.00 +/- 71.4 vs. 357.26 +/- 98.86 mg/dL). After simvastatin treatment it wasn't observed any significant correlation between the changes of hemostatic parameters and serum lipids.


CONCLUSIONS
The short therapy of simvastatin therapy beneficial modifies hemostatic parameters. Lack of linear correlation between lipids changes concentrations and hemostatic parameters during simvastatin treatment suggests hypolipemic independent influence of statin on the coagulation system.
Broncel
Marlena
M
Department of Internal Medicine with Clinical Pharmacology and Therapy Monitoring Unit, Medical University of Łódz, Poland. ttm@ttm.org.pl
Marczyk
Iwona
I
Kostka
Barbara
B
Michalska
Marta
M
Sikora
Joanna
J
Chojnowska-Jezierska
Julita
J
D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005170:Factor X / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D019821:Simvastatin / Q000627:therapeutic use*; D013223:Statistics as Topic / Q000379:methods; D013917:Thrombin / Q000032:analysis; D014280:Triglycerides / Q000097:blood
D015415:Biomarkers; D008078:Cholesterol, LDL; D014280:Triglycerides; D000990:Antithrombin III; D005170:Factor X; D005340:Fibrinogen; D002784:Cholesterol; D019821:Simvastatin; D013917:Thrombin